Regulation of p53-targeting microRNAs by polycyclic aromatic hydrocarbons: Implications in the etiology of multiple myeloma

Molecular Carcinogenesis

Volumn 54, Issue 10, 2015, Pages 1060-1069

  Gordon, Michael W ^a   Yan, Fang ^b   Zhong, Xiaoming ^c   Mazumder, Pranab Behari ^d   Xu Monette, Zijun Y ^e   Zou, Dehui ^e   Young, Ken H ^e   Ramos, Kenneth S ^a   Li, Yong ^a  

^a University of Louisville School of Medicine   (United States)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c HENAN UNIVERSITY   (China)

^d ASSAM UNIVERSITY   (India)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

MicroRNAs; Multiple myeloma; P53; Polycyclic aromatic hydrocarbons; Toxicants

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; AMPIROXICAM; AROMATIC HYDROCARBON RECEPTOR; BENZO[A]PYRENE; CARCINOGEN; DIAZEPAM; EPIGALLOCATECHIN GALLATE; FLUMAZENIL; GLIMEPIRIDE; METHANDRIOL; MICRORNA; MICRORNA 125B; MICRORNA 141; MICRORNA 15A; MICRORNA 16; MICRORNA 200A; MICRORNA 25; MICRORNA 92; POLYCYCLIC AROMATIC HYDROCARBON; POLYPHENON E; PROTEIN P53; RIFABUTIN; TRAMADOL; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; CATECHIN; TP53 PROTEIN, HUMAN;

ARTICLE; CANCER SCREENING; CELL SURVIVAL; DOWN REGULATION; FEMALE; GENE CLUSTER; GENE OVEREXPRESSION; GENE STRUCTURE; GENETIC SCREENING; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMOTER REGION; PROTEIN TARGETING; REGULATORY MECHANISM; SCREENING TEST; TEA; UPREGULATION; 3' UNTRANSLATED REGION; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GENETICS; HELA CELL LINE; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; BENZO(A)PYRENE; CARCINOGENS, ENVIRONMENTAL; CATECHIN; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; HELA CELLS; HUMANS; MICRORNAS; MULTIPLE MYELOMA; POLYCYCLIC HYDROCARBONS, AROMATIC; PROMOTER REGIONS, GENETIC; RECEPTORS, ARYL HYDROCARBON; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84941654334     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22175     Document Type: Article

References (61)

1. Shimizu Y, Kato H, Schull WJ. Studies of the mortality of A-bomb survivors. 9. Mortality, 1950-1985: Part 2. Cancer mortality based on the recently revised doses (DS86). Radiat Res 1990; 121:120-141.
2. Williams RR, Horm JW. Association of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients: Interview study from the Third National Cancer Survey. J Natl Cancer Inst 1977; 58:525-547.
3. Mills PK, Newell GR, Beeson WL, Fraser GE, Phillips RL. History of cigarette smoking and risk of leukemia and myeloma: Results from the Adventist Health Study. J Natl Cancer Inst 1990; 82:1832-1836.
4. Fernberg P, Odenbro A, Bellocco R, et al. Tobacco use, body mass index, and the risk of leukemia and multiple myeloma: A nationwide cohort study in Sweden. Cancer Res 2007; 67:5983-5986.
5. Psaltopoulou T, Sergentanis TN, Kanellias N, Kanavidis P, Terpos E, Dimopoulos MA. Tobacco smoking and risk of multiple myeloma: A meta-analysis of 40 observational studies. Int J Cancer 2013; 132:2413-2431.
6. Castillo JJ, Dhami PK, Curry S, Brennan K. No association between cigarette smoking and incidence of plasma cell myeloma: A meta-analysis of 17 observational studies. Am J Hematol 2012; 87:729-731.
7. Hattemer-Frey HA, Travis CC. Benzo-a-pyrene: Environmental partitioning and human exposure. Toxicol Ind Health 1991; 7:141-157.
8. Phillips DH. Fifty years of benzo(a)pyrene. Nature 1983; 303:468-472.
9. Pfeifer GP, Denissenko MF. Formation and repair of DNA lesions in the p53 gene: Relation to cancer mutations? Environ Mol Mutagen 1998; 31:197-205.
10. Committee to Review the Health Effects in Vietnam Veterans of Exposure to Herbicides. Cancer. In: Veterans and Agent Orange: Update 1998. Washington, D.C.: National Academy Press; 1999. pp. 265-406.
11. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-310.
12. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res 2004; 64:1546-1558.
13. Chng WJ, Price-Troska T, Gonzalez-Paz N, et al. Clinical significance of TP53 mutation in myeloma. Leukemia 2007; 21:582-584.
14. Kumar M, Lu Z, Takwi AAL, et al. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene 2011; 30:843-853.
15. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-297.
16. Le MTN, Teh C, Shyh-Chang N, et al. MicroRNA-125b is a novel negative regulator of p53. Genes Dev 2009; 23:862-876.
17. Hu W, Chan CS, Wu R, et al. Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol Cell 2010; 38:689-699.
18. Swarbrick A, Woods SL, Shaw A, et al. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med 2010; 16:1134-1140.
19. Neveu P, Kye MJ, Qi S, et al. MicroRNA profiling reveals two distinct p53-related human pluripotent stem cell states. Cell Stem Cell 2010; 7:671-681.
20. Tian S, Huang S, Wu S, Guo W, Li J, He X. MicroRNA-1285 inhibits the expression of p53 by directly targeting its 3' untranslated region. Biochem Biophy Res Commun 2010; 396:435-439.
21. Becker LE, Lu Z, Chen W, Xiong W, Kong M, Li Y. A systematic screen reveals microRNA clusters that significantly regulate four major signaling pathways. PLoS ONE 2012; 7:e48474.
22. Fabbri M, Bottoni A, Shimizu M, et al. Association of a MicroRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 2011; 305:59-67.
23. Herrera-Merchan A, Cerrato C, Luengo G, et al. miR-33-mediated downregulation of p53 controls hematopoietic stem cell self-renewal. Cell Cycle 2010; 9:3277-3285.
24. Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008; 105:12885-12890.
25. Corthals SL, Sun SM, Kuiper R, et al. MicroRNA signatures characterize multiple myeloma patients. Leukemia 2011; 25:1784-1789.
26. Lionetti M, Biasiolo M, Agnelli L, et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009; 114:e20-e26.
27. Chi J, Ballabio E, Chen XH, et al. MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct 2011; 6:23.
28. Harris SL, Levine AJ. The p53 pathway: Positive and negative feedback loops. Oncogene 2005; 24:2899-2908.
29. Ramos KS, Bowes RC III, Ou X, Weber TJ. Responses of vascular smooth muscle cells to toxic insult: Cellular and molecular perspectives for environmental toxicants. J Toxicol Environ Health 1994; 43:419-440.
30. Ventura A, Young AG, Winslow MM, et al. Targeted deletion reveals essential and overlapping functions of the miR-17∼92 family of miRNA clusters. Cell 2008; 132:875-886.
31. Suzuki S, Adachi A, Hiraiwa A, Ohashi M, Ishibashi M, Kiyono T. Cloning and characterization of human MCM7 promoter. Gene 1998; 216:85-91.
32. Ramos KS. Redox regulation of c-Ha-ras and osteopontin signaling in vascular smooth muscle cells: Implications in chemical atherogenesis. Annu Rev Pharmacol Toxicol 1999; 39:243-265.
33. Liu M-F, Jiang S, Lu Z, Young KH, Li Y. Physiological and pathological functions of mammalian MicroRNAs. In: McQueen CA, editor. Comprehensive toxicology, Second Edition. Volume Cellular and Molecular Toxicology. London, UK: Elsevier Science; 2010.
34. Volinia S, Galasso M, Costinean S, et al. Reprogramming of miRNA networks in cancer and leukemia. Genome Res 2010; 20:589-599.
35. Takwi A, Li Y, Buscaglia L, et al. A statin-regulated microRNA represses human c-Myc expression and function. EMBO Mol Med 2012; 4:896-909.
36. De Amicis F, Perri A, Vizza D, et al. Epigallocatechin gallate inhibits growth and epithelial-to-mesenchymal transition in human thyroid carcinoma cell lines. J Cell Physiol 2013; 228:2054-2062.
37. Jin L, Li C, Xu Y, et al. Epigallocatechin gallate promotes p53 accumulation and activity via the inhibition of MDM2-mediated p53 ubiquitination in human lung cancer cells. Oncol Rep 2013; 29:1983-1990.
38. Thakur VS, Gupta K, Gupta S. Green tea polyphenols increase p53 transcriptional activity and acetylation by suppressing class I histone deacetylases. Int J Oncol 2012; 41:353-361.
39. Hastak K, Gupta S, Ahmad N, Agarwal MK, Agarwal ML, Mukhtar H. Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 2003; 22:4851-4859.
40. Muto S, Yokoi T, Gondo Y, et al. Inhibition of benzo[a]pyrene-induced mutagenesis by (-)-epigallocatechin gallate in the lung of rpsL transgenic mice. Carcinogenesis 1999; 20:421-424.
41. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354:1362-1369.
42. Xiong W, Wu X, Starnes S, et al. An analysis of the clinical and biological significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 2008; 112:4235-4246.
43. Stuhmer T, Chatterjee M, Hildebrandt M, et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 2005; 106:3609-3617.
44. Karchner SI, Franks DG, Powell WH, Hahn ME. Regulatory interactions among three members of the vertebrate aryl hydrocarbon receptor family: AHR Repressor, AHR1, and AHR2. J Biol Chem 2002; 277:6949-6959.
45. Baba T, Mimura J, Gradin K, et al. Structure and expression of the Ah receptor repressor gene. J Biol Chem 2001; 276:33101-33110.
46. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471:467-472.
47. Zudaire E, Cuesta N, Murty V, et al. The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers. J Clin Invest 2008; 118:640-650.
48. Damiani LA, Yingling CM, Leng S, Romo PE, Nakamura J, Belinsky SA. Carcinogen-induced gene promoter hypermethylation is mediated by DNMT1 and causal for transformation of immortalized bronchial epithelial cells. Cancer Res 2008; 68:9005-9014.
49. Montoya-Durango DE, Liu Y, Teneng I, et al. Epigenetic control of mammalian LINE-1 retrotransposon by retinoblastoma proteins. Mutat Res 2009; 665:20-28.
50. Teneng I, Montoya-Durango DE, Quertermous JL, Lacy ME, Ramos KS. Reactivation of L1 retrotransposon by benzo(a)pyrene involves complex genetic and epigenetic regulation. Epigenetics 2011; 6:355-367.
51. Miller KP, Chen YH, Hastings VL, Bral CM, Ramos KS. Profiles of antioxidant/electrophile response element (ARE/EpRE) nuclear protein binding and c-Ha-ras transactivation in vascular smooth muscle cells treated with oxidative metabolites of benzo[a]pyrene. Biochem Pharmacol 2000; 60:1285-1296.
52. Miller KP, Ramos KS. Impact of cellular metabolism on the biological effects of benzo[a]pyrene and related hydrocarbons. Drug Metab Rev 2001; 33:1-35.
53. Viluksela M, Bager Y, Tuomisto JT, et al. Liver tumor-promoting activity of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) in TCDD-sensitive and TCDD-resistant rat strains. Cancer Res 2000; 60:6911-6920.
54. Singh NP, Singh UP, Singh B, Price RL, Nagarkatti M, Nagarkatti PS. Activation of aryl hydrocarbon receptor (AhR) leads to reciprocal epigenetic regulation of FoxP3 and IL-17 expression and amelioration of experimental colitis. PLoS ONE 2011; 6:e23522.
55. Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 2010; 9:57-67.
56. Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010; 28:172-176.
57. Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137:1005-1017.
58. Anderson MW, Goodin C, Zhang Y, et al. Effect of dietary green tea extract and aerosolized difluoromethylornithine during lung tumor progression in A/J strain mice. Carcinogenesis 2008; 29:1594-1600.
59. Gaynor PJ, Dowlen HH, Miller JK, Mueller FJ, Ramsey N. Response of lactating jersey cows fed concentrate twice daily by computer or in a total mixed ration. J Dairy Sci 1989; 72:1519-1527.
60. Yang CS, Wang X, Lu G, Picinich SC. Cancer prevention by tea: Animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 2009; 9:429-439.
61. Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loo pRT-PCR. Nucleic Acids Res 2005; 33:e179.